February 2022
Case Study: Driving Improved Health Outcomes by Mitigating Competitive Inhibition and Potential Adverse Events
DH is a 67-year-old female PACE participant with a history of gastroesophageal reflux disease (GERD), hyperlipidemia, overactive bladder, hypertension, vitamin D deficiency, asthma, osteoarthritis, depression, and insomnia. During a recent visit to the PACE center, DH expressed feeling more depressed lately.
Her MedWise Risk ScoreTM is 16 out of 50 (moderate risk), attributed to her anticholinergic burden, sedative burden and competitive inhibition interactions.
CareVention HealthCare Presents New Keep up with PACE Podcast Series
Listen in on the new Keep up with PACE podcast, hosted by Ankur Patel, MD, MBA, FAAFP, Chief Medical Officer, Tabula Rasa HealthCare (TRHC). During each episode, Dr. Patel will speak with some of the industry’s leading experts and explore strategies to grow PACE, discuss best practices and trends, and more. Shawn Bloom, President and CEO of the National PACE Association (NPA), joins Dr. Patel for the first episode to discuss the future of PACE, including the challenges and opportunities that lie ahead.

Dr. Patel, a former PACE medical director, is the author of the recently published book Age Is Just a Number: A Geriatrician’s Secrets for Getting the Most Out of Life.
Pharmacy Times Article: Preventing Drug Interactions and Related Opioid Overdoes through Patient Engagement
An article by Jacques Turgeon, BPharm, PhD, Chief Scientific Officer, TRHC and CEO of TRHC’s Precision Pharmacotherapy, Research, and Development Institute, was recently featured in Pharmacy Times. In the article, Dr. Turgeon explains how patient engagement with pharmacists can help prevent drug interactions and related opioid overdoses.

"When pharmacists engage with patients, the impact can be incredible," states Turgeon. "Pharmacists can get a more complete picture of potential drug interactions and ensure recommendations align with patients from an adherence perspective. The end result is greater attention to medication safety."
Tafamidis for the Treatment of Transthyretin Amyloid Cardiomyopathy Webinar and Panel Discussion
Tuesday, February 8, 2022
3 pm EST
Tafamidis costs PACE organizations an estimated $240,000 per participant annually. This webinar will provide an overview of the clinical and financial aspects of prescribing tafamidis, and its use in the treatment of transthyretin amyloid cardiomyopathy. PACE executive directors/CEOs, CFOs, medical directors, prescribers, and clinical pharmacists are invited to attend this webinar, which will include a panel discussion.

Learning Objectives:

  • Review the pathophysiology of transthyretin amyloid cardiomyopathy
  • Describe the mechanism of action of tafamidis
  • Discuss and analyze the findings of the ATTR-ACT trial
  • Assess the cost-effectiveness of tafamidis
  • Determine the potential place in therapy for tafamidis

Panel Discussion Guests: 

Mathew S. Maurer, MD
Geriatric Cardiologist, Medical Director, HCM Center
New York-Presbyterian Hospital/Columbia University Medical Center

Frederick Ruberg, MD
Cardiologist Associate Professor, Medicine and Amyloidosis Center
Boston University School of Medicine
Networking with CareKinesis and CareVention HealthCare
We always enjoy the opportunity to meet with our clients, and look forward to seeing you at the following events in 2022:

March

  • 7-9 - NHPCO Leadership and Advocacy Conference, Gaylord National Resort & Convention Center, National Harbor, MD
  • 7-9 - RISE National 2022, Gaylord Opryland Resort, Nashville, TN
  • 15 - PACE Association of Michigan Business Partners Meet & Greet, Embassy Suites Grand Rapids Downtown, Grand Rapids, MI
  • 28-29 - NPA Spring Policy Forum, Mayflower Hotel, Washington, DC

April

  • 8 - PACE of Michigan CEO Learning Circle Event (virtual)

June

  • 22-23 - CareVention HealthCare Advisory Summit for PACE Executives, Sanctuary Resort, Paradise Valley, AZ  

September

  • 15-16 - CareKinesis Clinical Advisory Panel Meeting, Ritz-Carlton, Orlando, FL 

We will continue to add additional networking opportunities to our calendar; updates will be communicated in future editions of this newsletter.
Webinars and Educational Offerings
CareKinesis offers live CE-accredited webinars through Tabula Rasa HealthCare University (TRHCU). Non-CE-accredited modules are also available on demand. New offerings for 2021 include MedWise® Science introduction sessions and COVID-19 immunization webinars.

February

8 - Tafamidis for the Treatment of Transthyretin Amyloid Cardiomyopathy
10 - EireneRx® 101
17 - MedWise® Science: An Introduction – PACE Clinician Orientation

For more information, contact your CareKinesis client liaison.